Global Vulvodynia Treatment Market, by Drug Class (Anticonvulsant, Tricyclic Antidepressant, Serotonin-norepinephrine reuptake inhibitors, Hormone, Nerve Block, Local Anesthetic, and Others), by Mode Of Administration (Oral, Topical, and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.
As per the report, the global vulvodynia treatment market is majorly driven by the factors like tampon insertion, prolonged sitting, cycling or horseback riding, sexual intercourse, extreme gynecologic examination, and wearing tight undergarments. Moreover, the growing issues and the increasing initiatives to create awareness about women healthcare coupled with the adoption of advanced technology in improving healthcare facilities are also expected to favor steady market growth during the forecast year. The involvement of diagnostic services for the betterment of existing treatment also boosts the growth of the market.
Other factors including the accessibility of numerous generic and authentic products, mounting the occurrence of vulvodynia, and the on-going research and development activities enhancing the effectiveness of the treatment also boost the market growth. For instance, an NIH-funded Harvard study revealed the count of approximately 6 million women in America is expected to suffer from Vulvodynia. On the contrary, extremely low awareness about the disease, its causes, and the treatment options in emerging nations coupled with the penetrating side effects resulting from the treatment medications likely to restrict the market growth. On the other hand, the extended availability of off-label drugs offers a lucrative growth opportunity during the upcoming years.